Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 7 of 7 clinical reviews.
A critical deep-dive into the TRAVERSE trial's enrollment biases, follow-up duration, generalizability gaps, statistical caveats, and conflict-of-interest considerations for testosterone replacement therapy cardiovascular safety.
Read clinical reviewA detailed breakdown of the TRAVERSE trial design, randomization, blinding, endpoint adjudication, and statistical framework that established cardiovascular safety of testosterone replacement therapy in hypogonadal men with elevated CV risk.
Read clinical reviewA deep-dive into cost-per-QALY modeling, payer coverage dynamics, list-price vs net-price realities, and individual patient value calculations drawn from the TRAVERSE trial of testosterone gel in hypogonadal men with elevated cardiovascular risk.
Read clinical reviewDeep dive into TRAVERSE trial follow-up and extension data on testosterone replacement therapy cardiovascular safety in hypogonadal men, including long-term MACE outcomes and emerging safety signals.
Read clinical reviewDeep-dive into the TRAVERSE trial's pre-specified and post-hoc subgroup analyses for testosterone gel in hypogonadal men with elevated cardiovascular risk, examining responses by age, BMI, baseline testosterone, race, and comorbidity burden.
Read clinical reviewA detailed plain-English breakdown of the TRAVERSE trial (2023), the largest randomized controlled trial of testosterone replacement therapy, which tested cardiovascular safety in over 5,200 hypogonadal men with elevated CV risk.
Read clinical reviewHow the TRAVERSE trial's cardiovascular safety data for testosterone replacement therapy should reshape prescribing decisions, guideline updates, and patient selection in 2024 and beyond.
Read clinical review